In Vivo Antitumor Activity of ONYX-015 Is Influenced by p53 Status and Is Augmented by Radiotherapy

Kenneth R. Rogulski; Svend O. Freytag; Kang Zhang; Jeff D. Gilbert; Dell L. Paielli; Jae Ho Kim; Carla C. Heise; David H. Kirn

Advances in Brief

In Vivo Antitumor Activity of ONYX-015 Is Influenced by p53 Status and Is Augmented by Radiotherapy

Kenneth R. Rogulski, Svend O. Freytag, Kang Zhang, Jeff D. Gilbert, Dell L. Paielli, Jae Ho Kim, Carla C. Heise and David H. Kirn

Kenneth R. Rogulski

Departments of Radiation Oncology and Molecular Biology, Henry Ford Health System, Detroit, Michigan 48202 [K. R. R., S. O. F., K. Z., J. D. G., D. L. P., J. H. K.], and ONYX Pharmaceuticals, Richmond, California 94806 [C. C. H., D. H. K.]

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Svend O. Freytag

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kang Zhang

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jeff D. Gilbert

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Dell L. Paielli

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jae Ho Kim

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Carla C. Heise

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

David H. Kirn

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

DOI: Published March 2000

Article
Figures & Data
Info & Metrics
PDF

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: February 2001 to January 2021

	Abstract	Full-text HTML	PDF
Total	1580	3714	1906

Cited By

Article Information

Volume 60, Issue 5, pp. 1193-1196

PubMed

10728673

Published By

American Association for Cancer Research

Print ISSN

0008-5472

Online ISSN

1538-7445

History

Received November 15, 1999
Accepted January 19, 2000
Published first March 1, 2000.

Author Information

Kenneth R. Rogulski,
Svend O. Freytag2,
Kang Zhang,
Jeff D. Gilbert,
Dell L. Paielli,
Jae Ho Kim,
Carla C. Heise, and
David H. Kirn

Departments of Radiation Oncology and Molecular Biology, Henry Ford Health System, Detroit, Michigan 48202 [K. R. R., S. O. F., K. Z., J. D. G., D. L. P., J. H. K.], and ONYX Pharmaceuticals, Richmond, California 94806 [C. C. H., D. H. K.]

View Full Text

PreviousNext

March 2000
Volume 60, Issue 5

Table of Contents

Search for this keyword

View this article with LENS

Open full page PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following In Vivo Antitumor Activity of ONYX-015 Is Influenced by p53 Status and Is Augmented by Radiotherapy

Message Subject (Your Name) has forwarded a page to you from Cancer Research

Message Body (Your Name) thought you would be interested in this article in Cancer Research.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

In Vivo Antitumor Activity of ONYX-015 Is Influenced by p53 Status and Is Augmented by Radiotherapy